(Q53260505)

12 May 2018

title

A rare point mutation in the Ras oncogene in hepatocellular carcinoma. (English)

1 reference

12 May 2018

author name string

Akinobu Taketomi

1

1 reference

12 May 2018

Ken Shirabe

2

1 reference

12 May 2018

Jun Muto

3

1 reference

12 May 2018

Shohei Yoshiya

4

1 reference

12 May 2018

Takashi Motomura

5

1 reference

12 May 2018

Yohei Mano

6

1 reference

12 May 2018

Tohru Ikegami

7

1 reference

12 May 2018

Tomoharu Yoshizumi

8

1 reference

12 May 2018

Kenji Sugio

9

1 reference

12 May 2018

Yoshihiko Maehara

10

1 reference

12 May 2018

publication date

26 December 2012

1 reference

12 May 2018

published in

Surgery Today

1 reference

12 May 2018

volume

43

1 reference

12 May 2018

issue

3

1 reference

12 May 2018

page(s)

289-292

1 reference

12 May 2018

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Clinical aspects of hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Resection and liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0462-8

ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis

21 January 2018

1 reference

12 December 2020

Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing

1 reference

12 December 2020

Point mutation, allelic loss and increased methylation of c-Ha-Ras gene in human hepatocellular carcinoma

1 reference

12 December 2020

Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks.

1 reference

12 December 2020

Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas

1 reference

12 December 2020

Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S00595-012-0462-8

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018